Vanguard Portfolio Management
ACRS icon

Vanguard Portfolio Management’s Aclaris Therapeutics ACRS Stock Holding History

Vanguard Portfolio Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.75M Sell
1,465,735
-190,331
-11% -$849K ﹤0.01% 2283
2026
Q1 		$6.21M Buy
+1,656,066
New +$5.59M ﹤0.01% 2260

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Portfolio Management's ACRS Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Aclaris Therapeutics (ACRS) stake by 11% in Q2 2026, selling an estimated $849K and leaving 1,465,735 shares worth $7.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2283.

Vanguard Portfolio Management first reported a position in ACRS in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Vanguard Portfolio Management held 1,465,735 shares of Aclaris Therapeutics worth $7.75M as of Q2 2026.
  • Vanguard Portfolio Management sold 190,331 Aclaris Therapeutics shares in Q2 2026, an estimated $849K.
  • Aclaris Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2283 holding.
  • Vanguard Portfolio Management first reported a position in Aclaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.